Dewpoint Therapeutics presents breakthrough drug candidate against aggressive cancers

These novel molecules are designed to influence certain disease-relevant mechanisms directly in the cell. In the case of DPTX3186, this is the inhibition of the protein beta-catenin, which plays a central role in the development and progression of various Wnt-dependent cancers such as colon and breast cancer.

Präclinical studies show promising results: DPTX3186 was able to significantly slow down or even completely stop tumour growth. The targeted effect is particularly remarkable: healthy cells remain largely undamaged. This means a potentially lower risk of side effects - a common problem with many cancer therapies.

Clinical trials are already in sight. In mid-2025, Dewpoint Therapeutics plans to submit the application for the first clinical trial (IND), which is scheduled to begin in the same year. The development is supported by a partnership with Evotec, a leading biotechnology company, which enables the fast and efficient preparation of the necessary documents with its INDiGO platform. „The nomination of this development candidate is an important milestone“, says Ameet Nathwani, CEO of Dewpoint Therapeutics. It emphasises the transformative potential of the company's proprietary technology, which has succeeded in addressing a target structure previously considered „untreatable“ and creating the basis for new treatment options.

Source: Press release Dewpoint Therapeutics from 28 October 2024